Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857246 · ClinicalTrials.gov registry record · Phase 2
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00857246 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 30 participants.
The verdict
NCT00857246, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
Interventions
- DRUG Cisplatin
- DRUG Cetuximab
- DRUG Irinotecan
- PROCEDURE Surgery
- DRUG 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-07 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857246
The ClinicalTrials.gov registry entry for NCT00857246 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00857246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857246 about?
NCT00857246 is a clinical study titled "Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer". This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
What is the current status of trial NCT00857246?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-07. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00857246?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (DRUG), Irinotecan (DRUG), Surgery (PROCEDURE), 5-FU (DRUG).
Who is sponsoring clinical trial NCT00857246?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.